ATAI Life Sciences (ATAI) Stock Forecast & Price Target

Compare

1,925 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ATAI Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

ATAI

Life Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ATAI Stock 12 Month Forecast

Average Price Target

$12.71

▲(193.53% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for ATAI Life Sciences in the last 3 months. The average price target is $12.71 with a high forecast of $16.00 and a low forecast of $10.00. The average price target represents a 193.53% change from the last price of $4.33.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","17":"$17","4.25":"$4.25","8.5":"$8.5","12.75":"$12.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4.25,8.5,12.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.775384615384615,5.71076923076923,6.646153846153846,7.581538461538461,8.516923076923078,9.452307692307691,10.387692307692308,11.323076923076922,12.258461538461539,13.193846153846154,14.12923076923077,15.064615384615385,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.522307692307693,5.204615384615384,5.886923076923077,6.569230769230769,7.251538461538462,7.933846153846154,8.616153846153846,9.298461538461538,9.980769230769232,10.663076923076924,11.345384615384617,12.027692307692309,{"y":12.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.84,4.313846153846153,4.787692307692308,5.2615384615384615,5.735384615384615,6.2092307692307696,6.683076923076923,7.156923076923077,7.63076923076923,8.104615384615386,8.57846153846154,9.052307692307693,9.526153846153846,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.69,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.55,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.71,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.59,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.84,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$16.00

Average Price Target$12.71

Lowest Price Target$10.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Michael Okunewitch

Maxim Group

$10

Buy

130.95%

Upside

Reiterated

11/18/25

AtaiBeckley: Strong Buy Rating Backed by Promising Clinical Data and Robust Financial Position

Patrick Trucchio

H.C. Wainwright

$15

Buy

246.42%

Upside

Reiterated

11/14/25

ATAI Life Sciences' BPL-003 Gains Momentum with Breakthrough Therapy Designation and Strategic Merger, Reinforcing Buy RatingWe value AtaiBeckley using a discounted cash flow (DCF)- and sum-of-the-parts (SOTP)- based methodology. We assign probabilities of success of 85% to to VLS-01. We model equity raises of $100M- $200M annually from 2026E-2028E to fund clinical and business development, which may dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x. We value AtaiBeckley-owned programs at $14/share, and COMPASS at $1/share.

Sumant Kulkarni

Canaccord Genuity

$14

Buy

223.33%

Upside

Reiterated

11/14/25

Canaccord Genuity Reaffirms Their Buy Rating on ATAI Life Sciences (ATAI)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

11/13/25

ATAI Life Sciences: Promising Clinical Developments and Strong Financial Position Drive Buy RatingWe believe ATAI is balancing complexity of an intermittent-dosing paradigm, the additive MADRS benefit from redosing, and safety, which we think will be key topics with FDA.

Ami Fadia

Needham

$12

Buy

177.14%

Upside

Reiterated

11/12/25

ATAI Life Sciences' BPL-003 Shows Promising Phase 2b Results, Earning Buy Rating

Jay Olson

Oppenheimer

$16

Buy

269.52%

Upside

Reiterated

11/06/25

ATAI Life Sciences (ATAI) Receives a Buy from Oppenheimer

Harry Gillis

Berenberg Bank

$12

Buy

177.14%

Upside

Reiterated

10/23/25

ATAI Life Sciences: Promising Growth in Psychedelics Market with Strong Pipeline and Strategic PositioningWe forecast 40% probability of USD4bn global peak sales, which could be achieved through penetration of just 5% of US TRD (equating to USD3bn in US sales). FDA breakthrough therapy designation reflects BPL-003’s significant promise.

Andrew Tsai

Jefferies

$7→$10

Buy

130.95%

Upside

Reiterated

10/17/25

Atai Life Sciences price target raised to $10 from $7 at JefferiesAtai Life Sciences price target raised to $10 from $7 at Jefferies

Nathan Weinstein

Aegis Capital

Buy

84.76%

Upside

Reiterated

07/02/25

Aegis Capital Remains a Buy on ATAI Life Sciences (ATAI)

Elemer Piros

Lucid Capital

$12

Buy

177.14%

Upside

Initiated

06/06/25

Atai Life Sciences initiated with a Buy at Lucid CapitalAtai Life Sciences initiated with a Buy at Lucid Capital

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Michael Okunewitch

Maxim Group

$10

Buy

130.95%

Upside

Reiterated

11/18/25

AtaiBeckley: Strong Buy Rating Backed by Promising Clinical Data and Robust Financial Position

Patrick Trucchio

H.C. Wainwright

$15

Buy

246.42%

Upside

Reiterated

11/14/25

Sumant Kulkarni

Canaccord Genuity

$14

Buy

223.33%

Upside

Reiterated

11/14/25

Canaccord Genuity Reaffirms Their Buy Rating on ATAI Life Sciences (ATAI)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

11/13/25

Ami Fadia

Needham

$12

Buy

177.14%

Upside

Reiterated

11/12/25

ATAI Life Sciences' BPL-003 Shows Promising Phase 2b Results, Earning Buy Rating

Jay Olson

Oppenheimer

$16

Buy

269.52%

Upside

Reiterated

11/06/25

ATAI Life Sciences (ATAI) Receives a Buy from Oppenheimer

Harry Gillis

Berenberg Bank

$12

Buy

177.14%

Upside

Reiterated

10/23/25

Andrew Tsai

Jefferies

$7→$10

Buy

130.95%

Upside

Reiterated

10/17/25

Atai Life Sciences price target raised to $10 from $7 at JefferiesAtai Life Sciences price target raised to $10 from $7 at Jefferies

Nathan Weinstein

Aegis Capital

Buy

84.76%

Upside

Reiterated

07/02/25

Aegis Capital Remains a Buy on ATAI Life Sciences (ATAI)

Elemer Piros

Lucid Capital

$12

Buy

177.14%

Upside

Initiated

06/06/25

Atai Life Sciences initiated with a Buy at Lucid CapitalAtai Life Sciences initiated with a Buy at Lucid Capital

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ATAI Life Sciences

1 Month

xxx

Success Rate

8/11 ratings generated profit

Average Return

+7.51%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +7.51% per trade.

3 Months

xxx

Success Rate

8/11 ratings generated profit

Average Return

+31.94%

reiterated a xxx

rating 25 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +31.94% per trade.

1 Year

Michael OkunewitchMaxim Group

Success Rate

8/11 ratings generated profit

Average Return

+68.51%

reiterated a buy rating 25 days ago

Copying Michael Okunewitch's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +68.51% per trade.

2 Years

xxx

Success Rate

13/14 ratings generated profit

Average Return

+141.25%

reiterated a xxx

rating 30 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 92.86% of your transactions generating a profit, with an average return of +141.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ATAI Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ATAI has received 11 Buy Ratings, 5 Hold Ratings, and 1 Sell Ratings. ATAI average Analyst price target in the past 3 months is 12.71.

Each month's total comprises the sum of three months' worth of ratings.

ATAI Financial Forecast

ATAI Earnings Forecast

Next quarter’s earnings estimate for ATAI is -$0.10 with a range of -$0.16 to -$0.07. The previous quarter’s EPS was -$0.28. ATAI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year ATAI has Performed in-line its overall industry.

ATAI Sales Forecast

Next quarter’s sales forecast for ATAI is $386.00K with a range of $0.00 to $1.50M. The previous quarter’s sales results were $749.00K. ATAI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year ATAI has Performed in-line its overall industry.

ATAI Stock Forecast FAQ

What is ATAI’s average 12-month price target, according to analysts?

Based on analyst ratings, ATAI Life Sciences’s 12-month average price target is 12.71.

What is ATAI’s upside potential, based on the analysts’ average price target?

ATAI Life Sciences has 193.53% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ATAI a Buy, Sell or Hold?

ATAI Life Sciences has a consensus rating of Strong Buy which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is ATAI Life Sciences’s price target?

The average price target for ATAI Life Sciences is 12.71. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $10.00. The average price target represents 193.53% Increase from the current price of $4.33.

What do analysts say about ATAI Life Sciences?

ATAI Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of ATAI?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

ATAI Life Sciences (ATAI) Stock Forecast & Price Target

ATAI Analyst Ratings

ATAI Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ATAI Life Sciences

ATAI Analyst Recommendation Trends

ATAI Financial Forecast

ATAI Earnings Forecast

ATAI Sales Forecast

ATAI Stock Forecast FAQ

Detailed List of Analyst Forecasts